Skip to content

A randomized controlled trial of laparoscopic cephlo-medial-to-lateral approach versus conventional medial approach for rectal cancer

Laparoscopic cephalo-to-medial-to-lateral approach versus conventional medial approach for rectal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008196
Enrollment
Unknown
Registered
2016-03-31
Start date
2016-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

cephalo-medial-to-lateral approach group:underwent laparoscopic cephlo-medial-to-lateral approach
conventional medial approach group:underwent conventional laparoscopic medial approach

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18, male or unpregnant female; 2. Diagnosed with rectal cancer by pre-operative colonoscopic biopsy; 3. Patients undergo radical surgery, with no distant metastases preoperation; 4. Elective surgery; 5. Patients undergo L-Dixon surgery with rectosigmoid anastomosis; 6. BMI between 18-30kg/m2; 7. Patients without other primary tumors; 8. Patients agree to undergo standard adjuvent therapy.; 9. Patients fully understand the aim of this trial,volunteer to be in and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with distant metastases, tumor infiltrating to adjacent organ or recurrent cases; 2. Patients underwent emergent surgery due to perforation, hemorrhage, intestinal obstruction, etc.; 3. Patients with severe cardiac, pulmonary, hepatic or renal comorbities and hence could tolerate laparoscopic surgery; 4. Patients with bad general condition and do not improve before surgery; 5. Patients with ultra-low rectal cancer and undergo L-IST, L-Hartmann, L-Miles's or prolapsing technique; 6. Patients who refuse to undergo standard adjuvent therapy.

Design outcomes

Primary

MeasureTime frame
Three-year overall survival;

Secondary

MeasureTime frame
three-year tumor recurrence;three-year tumor-free survival;

Countries

China

Contacts

Public ContactZheng Minhua

Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine

zmhtiger@yeah.net+86 13901785270

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026